Search in:

ClinicoEconomics and Outcomes Research Volume 7, 2015 - Issue

Submit an article Journal homepage

Open access

104

Views

CrossRef citations to date

Altmetric

Original Research

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

George Dranitsaris1 Augmentium Pharma Consulting Inc., Toronto, ON, CanadaCorrespondence[email protected]

Bo Yu2 Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China

Jennifer King3 Celgene Corporation, Summit, NJ, USA

Satyin Kaura3 Celgene Corporation, Summit, NJ, USA

Adams Zhang3 Celgene Corporation, Summit, NJ, USA

Pages 249-256 | Published online: 12 May 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (22)

Ignacio Martínez-Martel, Xue Bai, Gerard Batallé & Olga Pol. (2022) New Treatment for the Cognitive and Emotional Deficits Linked with Paclitaxel-Induced Peripheral Neuropathy in Mice. Antioxidants 11:12, pages 2387.
Crossref

Juanjuan Yang, Xiaojin Wang, Bingshun Wang, Kinam Park, Karen Wooley & Shiyi Zhang. (2022) Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers. Advanced Drug Delivery Reviews 190, pages 114525.
Crossref

Claudia Cristiano, Carmen Avagliano, Mariarosaria Cuozzo, Fabrizio Maria Liguori, Antonio Calignano & Roberto Russo. (2022) The Beneficial Effects of Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain and Associated Mood Disorders Induced by Paclitaxel in Mice. Biomolecules 12:8, pages 1155.
Crossref

Manraj N. Kaur, Jiajun Yan, Anne F. Klassen, Justin P. David, Dilshan Pieris, Manraj Sharma, Louise Bordeleau & Feng Xie. (2022) A Systematic Literature Review of Health Utility Values in Breast Cancer. Medical Decision Making 42:5, pages 704-719.
Crossref

Bo Shi, Wenbiao Ma, Hongshuai Pan, Yang Shi, Huan Zhang & Shenghai Xing. (2022) Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. Frontiers in Pharmacology 13.
Crossref

Yurong Ma, Wenwen Liu, Lingzhi Liang, Jiaqi Ye, Chaonan Huang, Tao Zhuang & Guisen Zhang. (2022) Synergistic Antinociceptive Effects of Indomethacin–Pregabalin and Meloxicam–Pregabalin in Paclitaxel-Induced Neuropathic Pain. Biomedicines 10:6, pages 1413.
Crossref

Zhichao Tian & Weitao Yao. (2022) Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas. Frontiers in Oncology 12.
Crossref

Huixin Xu, Yue Li, Jianming Guo, Yuan Sui, Baihui Chen, Dalin Li & Jiakang Jiang. (2021) A Meta-Analysis of the Efficacy of Albumin Paclitaxel versus Docetaxel in the Treatment of Breast Cancer. Journal of Healthcare Engineering 2021, pages 1-8.
Crossref

Jigang Chen, Mingyang Han, Aihua Liu & Bo Shi. (2021) Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US. Frontiers in Oncology 11.
Crossref

Dmitry A. Sychev, Olga D. Ostroumova, Liliya E. Ziganshina & Anastasiya V. Filippova. (2021) Drug-induced diarrhea associated with antineoplastic drugs. HERALD of North-Western State Medical University named after I.I. Mechnikov 13:3, pages 5-18.
Crossref

Leticia Rodrigues-Oliveira, Luiz Paulo Kowalski, Marcos Santos, Gustavo Nader Marta, René-Jean Bensadoun, Manoela Domingues Martins, Marcio Ajudarte Lopes, Gilberto de CastroJr.Jr., William Nassib WilliamJr.Jr., Aline Lauda Freitas Chaves, Cesar Augusto Migliorati, Ramzi G. Salloum, Carla Isabelly Rodrigues-Fernandes, Elisa Kauark-Fontes, Thaís Bianca Brandão, Alan Roger Santos-Silva & Ana Carolina Prado-Ribeiro. (2021) Direct costs associated with the management of mucositis: A systematic review. Oral Oncology 118, pages 105296.
Crossref

Huahua Zhang, Yandong Zhang, Chaonan Huang & Jiangfeng Wang. (2021) Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China. Clinical Drug Investigation 41:6, pages 569-577.
Crossref

Yimeng Chen, Baoshi Bao, Yao Lv, Decong Sun, Li Zhang, Jiandong Wang & Weihong Zhao. (2020) Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer. Investigational New Drugs 39:2, pages 524-529.
Crossref

Yingjie Zhang, Xiaohui Zeng, Haijun Deng, Fang Ma, Ye Peng, Lidan Yi, Chongqing Tan & Liubao Peng. (2019) Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2– Metastatic Breast Cancer From the US and Chinese Perspectives. Clinical Therapeutics 41:6, pages 1175-1185.
Crossref

Anagha Gogate, Jason S. Rotter, Justin G. Trogdon, Ke Meng, Christopher D. Baggett, Katherine E. Reeder-Hayes & Stephanie B. Wheeler. (2019) An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer. Breast Cancer Research and Treatment 174:2, pages 343-355.
Crossref

Jing Gao, Shougang Jiang, Xuewei Zhang, Yujie Fu & Zhiguo Liu. (2019) Preparation, characterization and in vitro activity of a docetaxel–albumin conjugate. Bioorganic Chemistry 83, pages 154-160.
Crossref

Lakshmi Pallavi Ganipineni, Fabienne Danhier & Véronique Préat. (2018) Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. Journal of Controlled Release 281, pages 42-57.
Crossref

S. Lauren Kyte, Wisam Toma, Deniz Bagdas, Julie A. Meade, Lesley D. Schurman, Aron H. Lichtman, Zhi-Jian Chen, Egidio Del Fabbro, Xianjun Fang, John W. Bigbee, M. Imad Damaj & David A. Gewirtz. (2018) Nicotine Prevents and Reverses Paclitaxel-Induced Mechanical Allodynia in a Mouse Model of CIPN. Journal of Pharmacology and Experimental Therapeutics 364:1, pages 110-119.
Crossref

Adam Brufsky. (2017) nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings. Experimental Hematology & Oncology 6:1.
Crossref

Alexandros Marios Sofias, Michael Dunne, Gert Storm & Christine Allen. (2017) The battle of “nano” paclitaxel. Advanced Drug Delivery Reviews 122, pages 20-30.
Crossref

Wisam Toma, S. Lauren Kyte, Deniz Bagdas, Yasmin Alkhlaif, Shakir D. Alsharari, Aron H. Lichtman, Zhi-Jian Chen, Egidio Del Fabbro, John W. Bigbee, David A. Gewirtz & M. Imad Damaj. (2017) Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse. Neuropharmacology 117, pages 305-315.
Crossref

L. Biganzoli, M. Aapro, Sibylle Loibl, Hans Wildiers & Etienne Brain. (2016) Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treatment Reviews 43, pages 19-26.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

Articles from other publishers (22)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

Citations (22)

Articles from other publishers (22)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date